Targeting Autophagy in ALK-Associated Cancers
Autophagy is an evolutionarily conserved catabolic process, which is used by the cells for cytoplasmic quality control. This process is induced following different kinds of stresses e.g., metabolic, environmental, or therapeutic, and acts, in this framework, as a cell survival mechanism. However, un...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/9/12/161 |
| _version_ | 1797701503974113280 |
|---|---|
| author | Julie Frentzel Domenico Sorrentino Sylvie Giuriato |
| author_facet | Julie Frentzel Domenico Sorrentino Sylvie Giuriato |
| author_sort | Julie Frentzel |
| collection | DOAJ |
| description | Autophagy is an evolutionarily conserved catabolic process, which is used by the cells for cytoplasmic quality control. This process is induced following different kinds of stresses e.g., metabolic, environmental, or therapeutic, and acts, in this framework, as a cell survival mechanism. However, under certain circumstances, autophagy has been associated with cell death. This duality has been extensively reported in solid and hematological cancers, and has been observed during both tumor development and cancer therapy. As autophagy plays a critical role at the crossroads between cell survival and cell death, its involvement and therapeutic modulation (either activation or inhibition) are currently intensively studied in cancer biology, to improve treatments and patient outcomes. Over the last few years, studies have demonstrated the occurrence of autophagy in different Anaplastic Lymphoma Kinase (ALK)-associated cancers, notably ALK-positive anaplastic large cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC), Neuroblastoma (NB), and Rhabdomyosarcoma (RMS). In this review, we will first briefly describe the autophagic process and how it can lead to opposite outcomes in anti-cancer therapies, and we will then focus on what is currently known regarding autophagy in ALK-associated cancers. |
| first_indexed | 2024-03-12T04:37:38Z |
| format | Article |
| id | doaj.art-0def6ef01bb84480a75d03e286581f91 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T04:37:38Z |
| publishDate | 2017-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0def6ef01bb84480a75d03e286581f912023-09-03T09:52:37ZengMDPI AGCancers2072-66942017-11-0191216110.3390/cancers9120161cancers9120161Targeting Autophagy in ALK-Associated CancersJulie Frentzel0Domenico Sorrentino1Sylvie Giuriato2Merck Serono S.A., Route de Fenil 25, Z.I. B, 1804 Corsier-sur-Vevey, SwitzerlandInserm, UMR1037, CNRS, ERL5294, Université Toulouse III-Paul Sabatier, CRCT, F-31000 Toulouse, FranceInserm, UMR1037, CNRS, ERL5294, Université Toulouse III-Paul Sabatier, CRCT, F-31000 Toulouse, FranceAutophagy is an evolutionarily conserved catabolic process, which is used by the cells for cytoplasmic quality control. This process is induced following different kinds of stresses e.g., metabolic, environmental, or therapeutic, and acts, in this framework, as a cell survival mechanism. However, under certain circumstances, autophagy has been associated with cell death. This duality has been extensively reported in solid and hematological cancers, and has been observed during both tumor development and cancer therapy. As autophagy plays a critical role at the crossroads between cell survival and cell death, its involvement and therapeutic modulation (either activation or inhibition) are currently intensively studied in cancer biology, to improve treatments and patient outcomes. Over the last few years, studies have demonstrated the occurrence of autophagy in different Anaplastic Lymphoma Kinase (ALK)-associated cancers, notably ALK-positive anaplastic large cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC), Neuroblastoma (NB), and Rhabdomyosarcoma (RMS). In this review, we will first briefly describe the autophagic process and how it can lead to opposite outcomes in anti-cancer therapies, and we will then focus on what is currently known regarding autophagy in ALK-associated cancers.https://www.mdpi.com/2072-6694/9/12/161ALK (anaplastic lymphoma kinase) oncogeneanaplastic large cell lymphoma (ALCL)non-small cell lung carcinoma (NSCLC)neuroblastoma (NB)rhabdomyosarcoma (RMS)tyrosine kinase inhibitor (TKI)combined therapycytoprotective autophagycytotoxic autophagyautophagic switch |
| spellingShingle | Julie Frentzel Domenico Sorrentino Sylvie Giuriato Targeting Autophagy in ALK-Associated Cancers Cancers ALK (anaplastic lymphoma kinase) oncogene anaplastic large cell lymphoma (ALCL) non-small cell lung carcinoma (NSCLC) neuroblastoma (NB) rhabdomyosarcoma (RMS) tyrosine kinase inhibitor (TKI) combined therapy cytoprotective autophagy cytotoxic autophagy autophagic switch |
| title | Targeting Autophagy in ALK-Associated Cancers |
| title_full | Targeting Autophagy in ALK-Associated Cancers |
| title_fullStr | Targeting Autophagy in ALK-Associated Cancers |
| title_full_unstemmed | Targeting Autophagy in ALK-Associated Cancers |
| title_short | Targeting Autophagy in ALK-Associated Cancers |
| title_sort | targeting autophagy in alk associated cancers |
| topic | ALK (anaplastic lymphoma kinase) oncogene anaplastic large cell lymphoma (ALCL) non-small cell lung carcinoma (NSCLC) neuroblastoma (NB) rhabdomyosarcoma (RMS) tyrosine kinase inhibitor (TKI) combined therapy cytoprotective autophagy cytotoxic autophagy autophagic switch |
| url | https://www.mdpi.com/2072-6694/9/12/161 |
| work_keys_str_mv | AT juliefrentzel targetingautophagyinalkassociatedcancers AT domenicosorrentino targetingautophagyinalkassociatedcancers AT sylviegiuriato targetingautophagyinalkassociatedcancers |